会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Chondroitin sulfate having decreased molecular weight and use thereof
    • 硫酸软骨素具有降低的分子量及其用途
    • US09149572B2
    • 2015-10-06
    • US13782165
    • 2013-03-01
    • Seikagaku Corporation
    • Kazuhiro KojimaYukio GotoHiroshi Maeda
    • A61M1/28A61K31/726A61K31/737C08B37/00C08J3/28C08L5/08
    • A61M1/287A61K31/726A61K31/737C08B37/0069C08J3/28C08J2305/08C08K3/02C08K3/08C08K5/09C08L5/08
    • A chondroitin sulfate having a decreased molecular weight which has utilization as an inhibitor of peritoneal disorder caused by long-term use of a peritoneal dialysis fluid containing glucose or a polysaccharide thereof as an osmotic agent, utilization as an osmotic agent in a peritoneal dialysis fluid, and the like. The chondroitin sulfate having a decreased molecular weight of the present invention as a means for achieving the object is characterized by having a weight average molecular weight of from 1000 to 20000 and containing a constituent disaccharide unit represented by the following structural formula in an amount of from 65% to 100% (molar ratio) of the total: -[4GlcAβ1-3GalNAc(6S)β1]- (wherein GlcA represents a D-glucuronic acid residue; GalNAc represents an N-acetyl-D-galactosamine residue; β1-3 represents a β1-3 glycosidic linkage; β1-4 represents a β1-4 glycosidic linkage; and (6S) indicates that position 6 of the monosaccharide residue is sulfated).
    • 具有降低的分子量的硫酸软骨素,其具有作为腹膜病的抑制剂的作用,其通过长期使用含有葡萄糖或其多糖的腹膜透析液作为渗透剂,在腹膜透析液中用作渗透剂, 等等。 本发明的分子量降低的硫酸软骨素作为实现目的的手段,其特征在于重均分子量为1000〜20000,含有下列结构式所示的构成二糖单元,其量为 65%至100%(摩尔比): - [4GlcA&bgr; 1-3GalNAc(6S)&bgr; 1] - (其中GlcA表示D-葡萄糖醛酸残基; GalNAc表示N-乙酰基-D-半乳糖胺残基 1-3表示1-3糖苷键; 1-4表示1-4糖苷键;(6S)表示单糖残基的6位硫酸化)。